Dr. Lal PathLabs Limited declared a final dividend of ₹4 per fully paid-up equity share for the financial year ended March 31, 2026, during its 32nd Annual General Meeting (AGM) held on July 25, 2026. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM) in compliance with the Companies Act, 2013 and Ministry of Corporate Affairs circulars, also approved the re-appointment of Executive Chairman (Hony) Brig Dr Arvind Lal and revised remuneration structures for senior leadership.

The AGM commenced at 10:00 A.M. (IST) and concluded at 11:03 A.M. (IST), with e-voting remaining open for an additional 15 minutes post-meeting. The proceedings were submitted to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 65 members participated via video conference, comprising 3 from the promoter group and 62 public shareholders.

Key Resolutions Passed

Shareholders approved several ordinary and special resolutions during the meeting. The Board confirmed that the Statutory Auditors' Report and Secretarial Auditor's Report for FY26 contained no qualifications or reservations.

Governance and Compliance

During the discussion on special resolutions regarding the remuneration and re-appointment of (Hony) Brig Dr Arvind Lal, the Chairperson was deemed interested and entrusted the conduct of proceedings to Mr. Arun Duggal, Lead Independent Director. Mr. Shankha Banerjee, Chief Executive Officer, addressed member queries during the Q&A session.

The Company engaged Central Depository Services (India) Limited (CDSL) for e-voting facilities, with remote voting available from July 21, 2026, to July 24, 2026. M/s. K.K Singh & Associates served as the Scrutinizer for the voting process. Statutory Auditors Deloitte Haskins & Sells LLP, Secretarial Auditors Chandrasekaran Associates, Cost Auditors A.G Agarwal & Associates, and Internal Auditors Ernst & Young LLP were present to represent their respective firms.

What the Numbers Show

The declaration of a ₹4 final dividend reflects the Company’s commitment to returning value to shareholders following the conclusion of FY26. With the unqualified audit reports from both statutory and secretarial auditors, the filing underscores strong corporate governance practices. The re-appointment of key leadership figures, including the Executive Chairman for a five-year term starting April 01, 2027, signals continuity in strategic direction amid evolving market conditions in the diagnostic sector.

Dr. Lal PathLabs Limited has secured a favourable outcome from the Commissioner of Income Tax (Appeals), which allowed its appeal concerning the disallowance of ESOP expenses. The appellate order, dated July 16, 2026, permits the company to claim a deduction of ₹32,66,18,927 on account of ESOP expenses. This decision reverses the position taken in the assessment order dated March 31, 2024, which had originally been contested by the diagnostic company.

The company received the communication on July 17, 2026. The order was passed under section 250 of the Income Tax Act, 1961, following an appeal filed against the earlier assessment. The resolution of this tax dispute removes a potential financial liability, as the deduction has now been formally recognized by the tax authorities.

Details of the Appellate Order

The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The specific details of the order are outlined below:

Vinay Gujral, Company Secretary & Compliance Officer, confirmed that the appeal was decided in the company's favour. The filing noted that there is no quantifiable adverse impact on the financial or operational activities of the listed entity resulting from this order.